US FDA warns surgeries over inappropriate advertising of Allergan's Lap-Band
This article was originally published in Clinica
Executive Summary
The US FDA has sent warning letters to several US institutions over misleading advertising of Allergan's gastric band Lap-Band. The letters, which went to eight surgical centres in California and the marketing firm 1-800-GET-THIN, said that their adverts for Lap-Band failed to provide required information on the risks and possible side-effects of the product. The FDA is also concerned that the font size of risk information on the advertising inserts is "too small to be read by customers".
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.